APLMW (Apollomics) PEG Ratio: N/A (As of Jun. 30, 2026)


APLMW Apollomics Inc APLMW
31 GF Score
Price $0.02
! 5 Warning Signs
View Full Analysis

What is Apollomics PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Apollomics's PE Ratio without NRI is 0.00. Apollomics's 5-Year EBITDA growth rate is -110.80%. Therefore, Apollomics's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Apollomics's PEG Ratio or its related term are showing as below:



APLMW's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.98
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.

Apollomics  (NAS:APLMW) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.

Apollomics PEG Ratio Related Terms

Apollomics PEG Ratio Historical Data

* Premium members only.

The historical data trend for Apollomics's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apollomics PEG Ratio Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

APLMW vs HYPD, MGX, KALA: PEG Ratio Comparison

For the Biotechnology subindustry, Apollomics's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apollomics PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apollomics's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Apollomics's PEG Ratio falls into.


APLMW
31GF Score
Apollomics Inc APLMW
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apollomics PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Apollomics's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/-110.80
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Apollomics Business Description

Other Exchanges APLM:USA
Address 989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
31GF Score

Get the complete analysis for APLMW

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price